title: Possible functional groups responsible for inhibition of in vivo angiogenesis by herbimycin A.
abstract: Six herbimycin A (HBM) derivatives were examined for their anti-angiogenic effects in a bioassay system involving chorioallantoic membranes (CAMs) of growing chick embryos on the basis of our previous observation that HBM is a potent angiogenesis inhibitor. 17-Cyclopropylamino-HBM dose-dependently inhibited embryonic angiogenesis. The ID50 value was 0.1 microgram (160 pmol) per egg and thereby lower than that of the parent compound HBM (ID50 = 0.15 micrograms (260 pmol) per egg). In contrast, 19-dimethylamino-, N-acetyl-, 2,3,4,5-tetrahydro- and 7-decarbamoyl-HBM at doses of 0.01-10 micrograms/egg failed to affect angiogenesis in CAMs. These results strongly suggest as follows: (1) C-19 position, amino group between positions C-1 and C-20 and carbamoyl group in C-7 are essential for the anti-angiogenic action of HBM; (2) HBM needs certain fixed conformation for expression of angiogenesis inhibition; (3) it is expected that the modification of C-17 with a suitable functional group results in increased anti-angiogenic potency of HBM--that is, a more potent angiogenesis inhibitor than the parent compound would be developed.
authors.affiliation: Department of Cancer Therapeutics, Tokyo Metropolitan Institute of Medical Science, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Oikawa
authors.forename: H
authors.initials: H
authors.lastname: Ogasawara
authors.forename: H
authors.initials: H
authors.lastname: Sano
authors.forename: K
authors.initials: K
authors.lastname: Shibata
authors.forename: S
authors.initials: S
authors.lastname: Omura
mesh_terms: D000482:Allantois / Q000098:blood supply / Q000187:drug effects*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D016227:Benzoquinones; D002642:Chick Embryo; D002823:Chorion / Q000098:blood supply / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D047029:Lactams, Macrocyclic; D007928:Lethal Dose 50; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D011809:Quinones / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D017828:Rifabutin / Q000031:analogs & derivatives; D013329:Structure-Activity Relationship
chemical_list: D000903:Antibiotics, Antineoplastic; D016227:Benzoquinones; D047029:Lactams, Macrocyclic; D011809:Quinones; D017828:Rifabutin; C020754:herbimycin